Condensed Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income
Beginning balance (in shares) at Mar. 31, 2021		69,377,567
Beginning balance at Mar. 31, 2021	$ 123,367	$ 1	$ 914,100	$ (791,069)	$ 335
Increase (Decrease) in Shareholders' Equity (Deficit)
Shares issued upon settlement of restricted stock units (in shares)		82,542
Shares sold in connection with at-the-market offering, net of brokerage fees and offering expenses (in shares)		179,400
Shares sold in connection with at-the-market offering, net of brokerage fees and offering expenses of $0.0 million	479		479
Stock-based compensation expense (benefits)	1,321		1,321
Foreign currency translation adjustment	2				2
Net loss	(11,870)			(11,870)
Ending balance (in shares) at Jun. 30, 2021		69,639,509
Ending balance at Jun. 30, 2021	113,299	$ 1	915,900	(802,939)	337
Beginning balance (in shares) at Mar. 31, 2021		69,377,567
Beginning balance at Mar. 31, 2021	123,367	$ 1	914,100	(791,069)	335
Increase (Decrease) in Shareholders' Equity (Deficit)
Foreign currency translation adjustment	2
Net loss	(33,107)
Ending balance (in shares) at Sep. 30, 2021		72,941,507
Ending balance at Sep. 30, 2021	99,360	$ 1	923,198	(824,176)	337
Beginning balance (in shares) at Mar. 31, 2021		69,377,567
Beginning balance at Mar. 31, 2021	123,367	$ 1	914,100	(791,069)	335
Increase (Decrease) in Shareholders' Equity (Deficit)
Net loss	(71,900)
Ending balance (in shares) at Mar. 31, 2022		73,739,378,000
Ending balance at Mar. 31, 2022	60,348	$ 1	922,966	(862,956)	337
Beginning balance (in shares) at Jun. 30, 2021		69,639,509
Beginning balance at Jun. 30, 2021	113,299	$ 1	915,900	(802,939)	337
Increase (Decrease) in Shareholders' Equity (Deficit)
Shares issued upon exercise of pre-funded warrants (in shares)		3,301,998
Stock-based compensation expense (benefits)	7,298		7,298
Foreign currency translation adjustment	0
Net loss	(21,237)			(21,237)
Ending balance (in shares) at Sep. 30, 2021		72,941,507
Ending balance at Sep. 30, 2021	99,360	$ 1	923,198	(824,176)	337
Beginning balance (in shares) at Mar. 31, 2022		73,739,378,000
Beginning balance at Mar. 31, 2022	60,348	$ 1	922,966	(862,956)	337
Increase (Decrease) in Shareholders' Equity (Deficit)
Shares issued upon settlement of restricted stock units (in shares)		235,818,000
Stock-based compensation expense (benefits)	(159)		(159)
Foreign currency translation adjustment	(4)				(4)
Net loss	(8,406)			(8,406)
Ending balance (in shares) at Jun. 30, 2022		73,975,196,000
Ending balance at Jun. 30, 2022	51,779	$ 1	922,807	(871,362)	333
Beginning balance (in shares) at Mar. 31, 2022		73,739,378,000
Beginning balance at Mar. 31, 2022	60,348	$ 1	922,966	(862,956)	337
Increase (Decrease) in Shareholders' Equity (Deficit)
Foreign currency translation adjustment	(6)
Net loss	(11,486)
Ending balance (in shares) at Sep. 30, 2022		73,975,196,000
Ending balance at Sep. 30, 2022	48,912	$ 1	923,022	(874,442)	331
Beginning balance (in shares) at Jun. 30, 2022		73,975,196,000
Beginning balance at Jun. 30, 2022	51,779	$ 1	922,807	(871,362)	333
Increase (Decrease) in Shareholders' Equity (Deficit)
Stock-based compensation expense (benefits)	215		215
Foreign currency translation adjustment	(2)				(2)
Net loss	(3,080)			(3,080)
Ending balance (in shares) at Sep. 30, 2022		73,975,196,000
Ending balance at Sep. 30, 2022	$ 48,912	$ 1	$ 923,022	$ (874,442)	$ 331